

PRESS RELEASE

IDOGEN AB



Org nr. 556756-8521

Date: 5th of December, 2016

Japan Patent Office intends to grant Idogen's patent application

Idogen AB ("Idogen") today announces that the Japan Patent Office ("JPO") has issued a "Notice of Allowance", which means that it intends to grant Idogen's patent application in Japan. The patent provides Idogen's vaccine technology with a broad protection and further strengthens the company's patent portfolio in an important market for Idogen.

The Japan Patent Office has communicated its intention to grant Idogen's Patent Application No. 2013-546073. The patent belongs to Idogen's second patent family and broadly covers Idogen's technology. Final grant of the patent by the JPO will take place following the payment of official fees by Idogen during the coming weeks.

"As another major market for our tolerogenic vaccine is now added to the patent portfolio, our future prospects are strengthened. The decision represents a clear increase in the value of our product portfolio.", CEO Lars Hedbys comments. "It is very pleasing that the Japan Patent Office intends to grant this patent."

A granted patent protects the technology for 20 years from the date of PCT filing, which means that Idogen's patent will provide protection in Japan until 2031. This patent is a member of Idogen's second patent family and covers induction of IDO for treatment of autoimmune diseases and transplant rejection. Related patent applications in this family are pending in Canada, Europe and the USA. Idogen's first patent family concerns additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs and is so far granted in Europe.

For additional information about Idogen, please contact:

Lars Hedbys, CEO

Tel: +46 (0)46-275 63 30

E-mail: lars.hedbys@idogen.com

This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU's Market Abuse Regulation. The information was submitted for publication through the above contact person on the 5th of December 2016.

Idogen develops tolerogenic vaccines which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement. The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company's technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com